MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Street Poller Media and The Boom of the Street Interview Ad Industry 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Rejects Apple Trade Secret Theft Claims 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Amazon Secures 200 MW Wind Power Deals in Sweden 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Add as a preferred source on Google
ALPHARETTA, Ga., March 21, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 1:30 p.m. ET at The Westin Grand Central Hotel in New York, NY.
A live webcast of the presentation can be accessed on the company’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for approximately 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This has the potential to offer meaningful treatment benefit to patients suffering from sight-threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts:
Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]
Charles Deignan
Chief Financial Officer
(678) 270-4005
[email protected]
